Top

Published in:

Open Access 01-12-2023 | Myocardial Infarction | Research

Normal thyroid stimulating hormone is associated with all-cause mortality in patients with acute myocardial infarction after percutaneous coronary intervention

Authors: Wei-cheng Ni, Shu-ting Kong, Ken Lin, Yu-heng Huang, Jun-feng Li, San-ling Shi, Yu-cheng Lu, Ling Cheng, Chang-xi Chen, Hao Zhou

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

Background

Circulating thyroid-stimulating hormone (TSH) levels within the normal reference range can affect the cardiovascular system. The present study investigated the prognostic value of normal TSH levels in patients presenting with acute myocardial infarction (AMI) following percutaneous coronary intervention (PCI).

Methods

Between January 2013 and July 2019, 1240 patients with AMI and normal thyroid function were enrolled and classified according to TSH tertile. The trial endpoint was all-cause mortality. The integrated discrimination index (IDI) and the net reclassification index (NRI) were used to assess the combined predictive values of the TSH levels and the Global Registry of Acute Coronary Events (GRACE) scores.

Results

After a median 44.25-month follow-up, 195 individuals died. Even after covariate adjustment by multivariate Cox regression (HR: 1.56; 95% CI 1.08–2.25; P = 0.017), the patients in the third TSH tertile were at the highest risk of all-cause mortality. A subgroup analysis revealed significant interactions between the TSH levels and the GRACE scores (high risk vs. low/medium risk) (P = 0.019). The addition of the TSH levels to the GRACE scores substantially improved the prediction of all-cause mortality, especially for high-risk patients (NRI = 0.239; IDI = 0.044; C-statistic value range 0.649–0.691; all significant).

Conclusions

The third TSH tertile is associated with a higher incidence of all-cause mortality than the first TSH tertile in high-risk patients presenting with AMI after PCI.

Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the society for cardiovascular angiography and interventions. Circulation. 2016;133(11):1135–47. https://doi.org/10.1161/CIR.0000000000000336.CrossRefPubMed

Silber S, Albertsson P, Avilés FF, et al. Guidelines for percutaneous coronary interventions. The task force for percutaneous coronary interventions of the European society of cardiology. Eur Heart J. 2005;26(8):804–47. https://doi.org/10.1093/eurheartj/ehi138.CrossRefPubMed

Müller P, Leow MK, Dietrich JW. Minor perturbations of thyroid homeostasis and major cardiovascular endpoints-Physiological mechanisms and clinical evidence. Front Cardiovasc Med. 2022;9:942971. https://doi.org/10.3389/fcvm.2022.942971.CrossRefPubMedPubMedCentral

Manolis AA, Manolis TA, Melita H, Manolis AS. Subclinical thyroid dysfunction and cardiovascular consequences: an alarming wake-up call? Trends Cardiovasc Med. 2020;30(2):57–69. https://doi.org/10.1016/j.tcm.2019.02.011.CrossRefPubMed

Chaker L, Razvi S, Bensenor IM, Azizi F, Pearce EN, Peeters RP. Hypothyroidism correction appears in Nat Rev Dis Primers. Nat Rev Dis Primers. 2022;8(1):30. https://doi.org/10.1038/s41572-022-00357-7.CrossRefPubMed

Åsvold BO, Vatten LJ, Midthjell K, Bjøro T. Serum TSH within the reference range as a predictor of future hypothyroidism and hyperthyroidism: 11-year follow-up of the HUNT Study in Norway. J Clin Endocrinol Metab. 2012;97(1):93–9. https://doi.org/10.1210/jc.2011-1724.CrossRefPubMed

Wartofsky L, Dickey RA. The evidence for a narrower thyrotropin reference range is compelling. J Clin Endocrinol Metab. 2005;90(9):5483–8. https://doi.org/10.1210/jc.2005-0455.CrossRefPubMed

Kuś A, Marouli E, Del Greco MF, et al. Variation in normal range thyroid function affects serum cholesterol levels, blood pressure, and type 2 diabetes risk: a Mendelian randomization study. Thyroid. 2021;31(5):721–31. https://doi.org/10.1089/thy.2020.0393.CrossRefPubMed

Ren R, Ma Y, Deng F, et al. Association between serum TSH levels and metabolic components in euthyroid subjects: a nationwide population-based study. Diabetes Metab Syndr Obes. 2019;12:1563–9. https://doi.org/10.2147/DMSO.S202769.CrossRefPubMedPubMedCentral

10.

Asvold BO, Bjøro T, Vatten LJ. Association of thyroid function with estimated glomerular filtration rate in a population-based study: the HUNT study. Eur J Endocrinol. 2011;164(1):101–5. https://doi.org/10.1530/EJE-10-0705.CrossRefPubMed

11.

Morishima I, Okumura K, Morita Y, et al. High-normal thyroid-stimulating hormone shows a potential causal association with arrhythmia recurrence after catheter ablation of atrial fibrillation. J Am Heart Assoc. 2018;7(14):e009158. https://doi.org/10.1161/JAHA.118.009158.CrossRefPubMedPubMedCentral

12.

Zhu P, Lao G, Chen C, Luo L, Gu J, Ran J. TSH levels within the normal range and risk of cardiovascular and all-cause mortality among individuals with diabetes. Cardiovasc Diabetol. 2022;21(1):254. https://doi.org/10.1186/s12933-022-01698-z.CrossRefPubMedPubMedCentral

13.

Gürdoğan M, Altay S, Korkmaz S, et al. The effect of thyroid stimulating hormone level within the reference range on in-hospital and short-term prognosis in acute coronary syndrome patients. Medicina (Kaunas). 2019;55(5):175. https://doi.org/10.3390/medicina55050175.CrossRefPubMed

14.

Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091. https://doi.org/10.1136/bmj.38985.646481.55.CrossRefPubMedPubMedCentral

15.

Antunes TT, Gagnon A, Bell A, Sorisky A. Thyroid-stimulating hormone stimulates interleukin-6 release from 3T3-L1 adipocytes through a cAMP-protein kinase A pathway. Obes Res. 2005;13(12):2066–71. https://doi.org/10.1038/oby.2005.256.CrossRefPubMed

16.

Wang HC, Dragoo J, Zhou Q, Klein JR. An intrinsic thyrotropin-mediated pathway of TNF-alpha production by bone marrow cells. Blood. 2003;101(1):119–23. https://doi.org/10.1182/blood-2002-02-0544.CrossRefPubMed

17.

Giusti M, Valenti S, Guazzini B, et al. Circulating nitric oxide is modulated by recombinant human TSH administration during monitoring of thyroid cancer remnant. J Endocrinol Invest. 2003;26(12):1192–7. https://doi.org/10.1007/BF03349156.CrossRefPubMed

18.

Kahaly GJ. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid. 2000;10(8):665–79. https://doi.org/10.1089/10507250050137743.CrossRefPubMed

19.

Viswanathan G, Balasubramaniam K, Hardy R, Marshall S, Zaman A, Razvi S. Blood thrombogenicity is independently associated with serum TSH levels in post-non-ST elevation acute coronary syndrome. J Clin Endocrinol Metab. 2014;99(6):E1050–4. https://doi.org/10.1210/jc.2013-3062.CrossRefPubMed

20.

Huang W, Xu J, Jing F, et al. Functional thyrotropin receptor expression in the ventricle and the effects on ventricular BNP secretion. Endocrine. 2014;46(2):328–39. https://doi.org/10.1007/s12020-013-0052-6.CrossRefPubMed

21.

Asvold BO, Bjøro T, Platou C, Vatten LJ. Thyroid function and the risk of coronary heart disease: 12-year follow-up of the HUNT study in Norway. Clin Endocrinol (Oxf). 2012;77(6):911–7. https://doi.org/10.1111/j.1365-2265.2012.04477.x.CrossRefPubMed

22.

Inoue K, Ritz B, Brent GA, Ebrahimi R, Rhee CM, Leung AM. Association of subclinical hypothyroidism and cardiovascular disease with mortality. JAMA Netw Open. 2020;3(2):e1920745. https://doi.org/10.1001/jamanetworkopen.2019.20745.CrossRefPubMed

23.

Li X, Yao Y, Chen Z, et al. Thyroid-stimulating hormone within the normal range and risk of major adverse cardiovascular events in nonischemic dilated cardiomyopathy patients with severe left ventricular dysfunction. Clin Cardiol. 2019;42(1):120–8. https://doi.org/10.1002/clc.23117.CrossRefPubMed

24.

Ndrepepa G, Braun S, Mayer K, et al. Prognostic value of thyroid-stimulating hormone within reference range in patients with coronary artery disease. Metabolism. 2015;64(10):1308–15. https://doi.org/10.1016/j.metabol.2015.07.009.CrossRefPubMed

25.

Åsvold BO, Vatten LJ, Bjøro T, et al. Thyroid function within the normal range and risk of coronary heart disease: an individual participant data analysis of 14 cohorts. JAMA Intern Med. 2015;175(6):1037–47. https://doi.org/10.1001/jamainternmed.2015.0930.CrossRefPubMedPubMedCentral

26.

Sun L, Xiao K, Miao Z, et al. Prognostic value of normal thyroid stimulating hormone in long-term mortality in patients with STEMI. Front Endocrinol (Lausanne). 2022;13:806997. https://doi.org/10.3389/fendo.2022.806997.CrossRefPubMed

27.

Zhu Y, Shen J, Xue Y, et al. The association between thyroid-stimulating hormone and long-term outcomes in patients with ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention. Int J Gen Med. 2021;14:6295–303. https://doi.org/10.2147/IJGM.S333322.CrossRefPubMedPubMedCentral

28.

Iervasi G, Pingitore A, Landi P, et al. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation. 2003;107(5):708–13. https://doi.org/10.1161/01.cir.0000048124.64204.3f.CrossRefPubMed

29.

Fliers E, Bianco AC, Langouche L, Boelen A. Thyroid function in critically ill patients. Lancet Diabetes Endocrinol. 2015;3(10):816–25. https://doi.org/10.1016/S2213-8587(15)00225-9.CrossRefPubMedPubMedCentral

30.

Fliers E, Alkemade A, Wiersinga WM. The hypothalamic-pituitary-thyroid axis in critical illness. Best Pract Res Clin Endocrinol Metab. 2001;15(4):453–64. https://doi.org/10.1053/beem.2001.0163.CrossRefPubMed

31.

Rencuzogullari I, Çağdaş M, Karabağ Y, et al. Value of syntax score II for predicting in-hospital and long-term survival in octogenarians with ST-segment elevation myocardial infarction: a comparison of six different risk scores. Arch Gerontol Geriatr. 2019;83:37–43. https://doi.org/10.1016/j.archger.2019.03.016.CrossRefPubMed

32.

Pantos CI, Trikas AG, Pissimisis EG, et al. Effects of acute triiodothyronine treatment in patients with anterior myocardial infarction undergoing primary angioplasty: evidence from a pilot randomized clinical trial (ThyRepair Study). Thyroid. 2022;32(6):714–24. https://doi.org/10.1089/thy.2021.0596.CrossRefPubMed

33.

Jabbar A, Ingoe L, Junejo S, et al. Effect of levothyroxine on left ventricular ejection fraction in patients with subclinical hypothyroidism and acute myocardial infarction: a randomized clinical trial. JAMA. 2020;324(3):249–58. https://doi.org/10.1001/jama.2020.9389.CrossRefPubMed

34.

Yildiz I, Rencüzoğulları I, Karabağ Y, Karakayali M, Artac I, Gurevin MS. Predictors of left ventricular ejection function decline in young patients with ST-segment elevation myocardial infarction. Rev Assoc Med Bras. 2022;68(6):802–7. https://doi.org/10.1590/1806-9282.20220033.CrossRefPubMedPubMedCentral

35.

Ozbeyaz NB, Gokalp G, Algul E, et al. H2FPEF score and contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Angiology. 2023;74(2):181–8. https://doi.org/10.1177/00033197221099425.CrossRefPubMed

36.

Algül E, Özbeyaz NB, Şahan HF, Aydınyılmaz F, Sunman H, Tulmaç M. Stress hyperglycemia ratio is associated with high thrombus burden in patients with acute coronary syndrome. Angiology. 2023. https://doi.org/10.1177/00033197231167054.CrossRefPubMed

37.

Larisch R, Giacobino A, Eckl W, Wahl HG, Midgley JE, Hoermann R. Reference range for thyrotropin Post hoc assessment. Nuklearmedizin. 2015;54(3):112–7. https://doi.org/10.3413/Nukmed-0671-14-06.CrossRefPubMed

38.

Razvi S, Bhana S, Mrabeti S. Challenges in interpreting thyroid stimulating hormone results in the diagnosis of thyroid dysfunction. J Thyroid Res. 2019;2019:4106816. https://doi.org/10.1155/2019/4106816.CrossRefPubMedPubMedCentral

39.

Escobar-Morreale HF, Botella-Carretero JI, Escobar del Rey F, Morreale de Escobar G. REVIEW: treatment of hypothyroidism with combinations of levothyroxine plus liothyronine. J Clin Endocrinol Metab. 2005;90(8):4946–54. https://doi.org/10.1210/jc.2005-0184.CrossRefPubMed

Title: Normal thyroid stimulating hormone is associated with all-cause mortality in patients with acute myocardial infarction after percutaneous coronary intervention
Authors: Wei-cheng Ni
Shu-ting Kong
Ken Lin
Yu-heng Huang
Jun-feng Li
San-ling Shi
Yu-cheng Lu
Ling Cheng
Chang-xi Chen
Hao Zhou
Publication date: 01-12-2023
Publisher: BioMed Central
Keyword: Myocardial Infarction
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-023-01149-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Normal thyroid stimulating hormone is associated with all-cause mortality in patients with acute myocardial infarction after percutaneous coronary intervention

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Pro-fibrotic and apoptotic activities of circARAP1 in myocardial ischemia–reperfusion injury

Comparison of post-COVID-19 vaccination hypermetabolic lymphadenopathy on 18F-fluorodeoxyglucose PET/CT between virus-vector vaccine and mRNA vaccine

Prognosis of coronary heart disease after percutaneous coronary intervention: a bibliometric analysis over the period 2004–2022

Relationship between neutrophil to lymphocyte ratio and diabetic peripheral neuropathy: a systematic review and meta-analysis

Significant increase of serum extracellular vesicle-packaged growth differentiation factor 15 in type 2 diabetes mellitus: a cross-sectional study

Nomogram for predicting survival in patients with mucinous breast cancer undergoing chemotherapy and surgery: a population-based study